Brii Bio nabs Gilead exec as SVP & head of US market access

Sino-American company Brii Biosciences (HKG: 2137) today announced the appointment of Coy Stout as senior vice president and head of US market access and patient advocacy.

Mr Stout brings with him more than 25 years of experience as a leader in public health and the biopharmaceutical industry, establishing strategic commercial planning and infrastructure to help advance patient access in the US to important medications across a variety of disease areas, especially infectious diseases.

Prior to joining Brii Bio, Mr Stout served as the VP of US commercial access and reimbursement overseeing key federal accounts at Gilead Sciences (Nasdaq: GILD). He held increasing leadership positions at Gilead during his 17-year tenure, including roles focused on commercial access and reimbursement and working closely with government affairs and policy teams to inform product planning initiatives.